Insights

Best-practice writing for regulatory documents.

Practical guidance on the documents Vertex templates support. Each article includes concrete before-and-after example text — the same wedge that ships in the templates. No keyword-stuffed SEO filler.

Live articles

Published.

IB

Crafting an IB that stands up to FDA review

What separates an Investigator's Brochure that earns a clean IND from one that triggers an information request. Section-by-section, with sample text drawn from the Vertex template.

  • 21 CFR 312.55
  • ICH E6(R2)
  • RSI
Read the article
In progress

Coming soon.

M2.7

Module 2.7 Clinical Summary structure, simplified

The four 2.7 subsections, what each one is supposed to do, and where writers most often misplace content between them.

  • ICH M4E(R2)
  • 2.7.1–2.7.6
M11

ICH M11 protocol template — what changed and why

Structural shifts in M11 vs ICH E6 and the practical implications for drafting, reviewing, and amending protocols.

  • ICH M11
  • USDM
  • CDISC
CSR

Writing CSR results sections that feed Module 2.7 cleanly

How to draft efficacy and safety results in the CSR so that 2.7.3 and 2.7.4 lift cleanly without rewriting.

  • ICH E3
  • 2.7.3 / 2.7.4
M2.5

Benefit-risk language reviewers actually accept

The phrasing patterns that survive FDA review without triggering information requests on Module 2.5 benefit-risk conclusions.

  • ICH M4E(R2)
  • 2.5.6
DSUR

Annual DSUR signal evaluation that doesn't restart from scratch

Structuring the DSUR so each year's safety signal evaluation builds on last year's instead of regenerating from MedDRA tables.

  • ICH E2F
PRE-IND

Pre-IND briefing book questions that get useful answers

How to phrase Type B meeting questions for cleanest agency response — yes/no, agree/disagree, acceptable-approach framing.

  • FDA Type B
  • Pre-IND

Want the templates these articles describe?

Every article is anchored to a Vertex template. Demo runs the actual document, not a slide.

Schedule a Demo Explore Solutions